Tag: treatment

Search
Generic filters
Exact matches only

AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Press release originally published May 17, 2022 on Avrobio.com. New early data show key visual motor integration, visual perception...

read more

Q & A on Cystaran Eye Drops

Leadiant, the makers of Cystaran eye drops, are opening up the floor for a Town Hall Q&A on Wednesday,...

read more

May 2021 Cystaran Update

Please click here for the latest updates from Leadiant on the Cystadrops shortage. If you have further questions, please...

read more

Update: Cystaran Eye Drop Shortage

As of today, November 12th, AllianceRx Walgreens Prime is unable to fulfill any orders of CYSTARAN. Leadiant’s full announcement...

read more

CYSTARAN Eye Drop Shortage Anticipated

In a statement from Leadient Biosciences on October 9th, the company announced an availability shortage may impact cystinosis patients...

read more

Recordati Announces Availability of CYSTADROPS in the U.S.

Beginning September 15, 2020, Recordati Rare Diseases announced the availability of CYSTADROPS across the United States. CYSTADROPS are a...

read more

Announcement from Leadient

To address the shortage of Cystaran eye drops some members of our community may have encountered recently, Leadient Biosciences...

read more

FDA Approves CYSTADROPS®

Recordati announced approval of an eye drop treatment to reduce corneal crystals. “We are pleased to bring Cystadrops® to...

read more

Program to Advance Cystinosis Treatment Options

Partnering with RDMD, this program aims to accelerate cystinosis research to ultimately improve treatment options. We welcome you to...

read more

Second Patient Dosed in Gene Therapy Trial

AVROBIO announces the second patient with cystinosis has been dosed in the company’s AVR-RD-04 investigational gene therapy Phase 1/2...

read more